Immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
Advancements in use of combination drugs in clinical trials: nivolumab, pembrolizumab, and more
An MRI-based approach to prostate cancer diagnosis: a urologist’s stance in the debate
What can histology tell us to ProtecT against prostate cancer?
Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC